Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25321403 | 0.96 | PRMT5 (0.39) | KDM1APDE1CPRMT5AR | |
| SCHEMBL30551015 | 0.96 | PRMT5 (0.39) | KDM1APDE1CPRMT5AR | |
| SCHEMBL25917473 | 0.89 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL30551031 | 0.89 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL25319343 | 0.89 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL25319349 | 0.89 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL30886312 | 0.86 | PDE1C (0.47) | KDM1APDE1CPRMT5WDR77 | |
| SCHEMBL30551523 | 0.85 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL25322716 | 0.85 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL25324213 | 0.83 | PRMT5 (0.41) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | KDM1A 1016/4885PDE1C 4035/4885PRMT5 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.